Yet, there is evidence suggesting that tumors harboring these gene fusions can be responsive to anti-MET monotherapy, as seen with PTPRZ1-MET in pediatric gliomas [87] and KIF5B-MET in lung cancers [88]. The gene discussed is MET; the disease is glioma.